Navina vs Reveleer
The prospective against the retrospective answer to the same contract, and most organisations under risk need both. Navina works inside the visit, surfacing suspected conditions with evidence attached so the clinician documents while the patient is in front of them. Reveleer works after it, retrieving records, parsing charts and populating risk adjustment and quality submissions, which is the machinery that closes a year once the visits are gone. The difference in cost and posture is real: prospective work improves the encounter and the documentation together, retrospective work recovers what the encounter missed and looks more like an audit than like care. Both vendors have the same unanswered question, which is what proportion of the conditions they surface a clinician confirms, and whether either flags codes that should come off as readily as codes that should go on.
- Prospective rather than retrospective. Conditions are surfaced to the clinician during the encounter with evidence attached, so documentation happens while the patient is present rather than through a chart chase afterwards.
- Proprietary language models classify documents and extract structure from free text across the record, exchanges and claims, which is a broader input set than record retrieval alone.
- Named and typed certifications, ISO 27001 and SOC 2 Type II with the type stated, plus native bidirectional integration in workflow.
- Retrospective completeness is a different job and this platform is built for it, automating record retrieval, parsing charts and populating both risk adjustment and quality submissions.
- Retrieval is the hard part of retrospective work and it owns that step rather than assuming the charts arrive, which is what determines whether a submission is complete.
- Quality reporting sits alongside risk adjustment in the same platform, so one workflow serves two regulatory obligations rather than two vendors serving one each.
Side by Side
| Axis | N Navina |
R Reveleer |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Autonomous Medical Coding page.
Prospective and retrospective risk adjustment are complementary and most risk bearing organisations run both, so treat this as a sequencing question rather than a choice. The governance issue is the same on both sides and neither addresses it: a platform that surfaces more diagnoses raises risk adjusted revenue whether or not the patient is sicker, and neither vendor publishes a confirmation rate, an add to delete ratio, or evidence that it flags codes lacking documentation for removal as readily as it suggests additions. Ask both for the two way number. Neither publishes pricing.